Earnings summaries and quarterly performance for Ardent Health.
Executive leadership at Ardent Health.
Board of directors at Ardent Health.
Edmondo Robinson
Detailed
Director
Ellen Havdala
Detailed
Director
Mark Sotir
Detailed
Chairman of the Board
Peter Bulgarelli
Detailed
Director
Peter Bynoe
Detailed
Director
Rahul Sen
Detailed
Director
Rob Webb
Detailed
Director
Robert A. DeMichiei
Detailed
Director
Suzanne Campion
Detailed
Director
William Goodyear
Detailed
Director
Research analysts who have asked questions during Ardent Health earnings calls.
Benjamin Hendrix
RBC Capital Markets
4 questions for ARDT
Also covers: ACHC, ADUS, AHCO +25 more
Benjamin Rossi
JPMorgan Chase & Co.
4 questions for ARDT
Also covers: AMED, AVAH, CON +7 more
Craig Hettenbach
Morgan Stanley
4 questions for ARDT
Also covers: ACCD, AMWL, DH +10 more
Matthew Gillmor
KeyCorp
4 questions for ARDT
Also covers: ACHC, ADUS, ALHC +11 more
Ann Hynes
Mizuho Financial Group
2 questions for ARDT
Also covers: BTSG, CI, CNC +17 more
Benjamin Mayo
Leerink Partners
2 questions for ARDT
Also covers: ACHC, AGL, AMED +10 more
Joanna Gajuk
Bank of America
2 questions for ARDT
Also covers: ACHC, ADUS, AGL +21 more
Scott Fidel
Stephens Inc.
2 questions for ARDT
Also covers: ACHC, ADUS, ALHC +17 more
Timothy Greaves
Loop Capital Markets LLC
2 questions for ARDT
Also covers: PRCH, WEAV
Jason Cassorla
Guggenheim Partners
1 question for ARDT
Also covers: ACHC, CI, CYH +8 more
Kevin Fischbeck
Bank of America
1 question for ARDT
Also covers: AMN, CCRN, CI +9 more
Raj Kumar
Stephens
1 question for ARDT
Also covers: ACHC, ADUS, AVAH +7 more
Whit Mayo
Leerink Partners
1 question for ARDT
Also covers: ACHC, AHCO, ALHC +11 more
Recent press releases and 8-K filings for ARDT.
Ardent Health Investigated for Securities Violations
ARDT
Legal Proceedings
Accounting Changes
Profit Warning
- Bleichmar Fonti & Auld LLP is investigating Ardent Health, Inc. for potential violations of federal securities laws.
- The investigation centers on Ardent's alleged improper accounting for its accounts receivable and professional liability reserves.
- Ardent's stock dropped over 33% on November 13, 2025, following the release of its Q3 2025 financial results.
- The Q3 2025 results, reported on November 12, 2025, revealed a $43 million decrease in revenue and a $54 million increase in professional liability reserves.
7 days ago
Ardent Health Faces Investigation Over $97 Million Accounting Adjustments
ARDT
Legal Proceedings
Accounting Changes
Guidance Update
- Shareholder rights law firm Hagens Berman has initiated an investigation into Ardent Health (ARDT) for potential securities law violations after the company's Q3 2025 financial disclosures revealed $97 million in adverse accounting adjustments.
- These adjustments, which caused the stock to tumble over 33%, include a $43 million revenue reduction due to collectability estimates and a $54 million increase in professional liability reserves.
- The investigation focuses on whether Ardent's leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves, and the significant cut to 2025 Adjusted EBITDA guidance.
8 days ago
Ardent Health Shares Decline Following Q3 2025 Results and Guidance Revision
ARDT
Earnings
Guidance Update
Legal Proceedings
- Ardent Health's shares tumbled $4.75 (-33%) on November 13, 2025, after the company announced its Q3 2025 financial results, which widely missed consensus EPS estimates and revealed two adverse non-recurring items.
- For Q3 2025, the company reported an EPS of -$0.17, a 189% decrease from the prior year period, and disclosed a $43 million adjustment that reduced revenue due to a modified technique for estimating accounts receivable collectability.
- Additionally, Ardent Health recorded a $54 million increase to its professional and general liability reserves, attributed to adverse prior period claim developments.
- The company significantly reduced its 2025 adjusted EBITDA guidance to $530-$550 million from $575-$615 million, representing a 9% decrease at the midpoint, partly blaming durable payor denials.
- Shareholder rights law firm Hagens Berman has opened an investigation into whether Ardent Health may have violated federal securities laws, focusing on the propriety of its financial statements, accounts receivable collectability, and professional liability reserves.
Nov 26, 2025, 1:50 PM
Ardent Health Reports Q3 2025 Results, Faces Investor Scrutiny
ARDT
Earnings
Profit Warning
Accounting Changes
- Ardent Health's shares tumbled $4.75 (-33%) on November 13, 2025, after the company announced its Q3 2025 financial results, which widely missed consensus EPS estimates.
- For Q3 2025, the company reported an EPS of -$0.17, a 189% decrease from the prior year period.
- The company revealed a $43 million adjustment that reduced revenue due to a modified technique for estimating accounts receivable collectability and a $54 million increase to its professional and general liability reserves.
- Ardent Health also reduced its 2025 adjusted EBITDA guidance to $530-$550 million from $575-$615 million, a 9% decrease at the midpoint, citing durable payor denials.
- Shareholder rights law firm Hagens Berman has opened an investigation into Ardent Health regarding potential violations of federal securities laws, focusing on the company's financial condition statements and accounting practices.
Nov 19, 2025, 9:56 PM
Ardent Health Announces $50 Million Share Repurchase Program
ARDT
Share Buyback
New Projects/Investments
- Ardent Health's Board of Directors authorized a $50 million share repurchase program on November 17, 2025.
- The program, which has no specified expiration date, will be funded from existing cash resources and ongoing cash from operations.
- As of the end of Q3 2025, Ardent Health reported a strong liquidity position with $609 million of cash and a lease-adjusted net leverage of 2.5x.
Nov 18, 2025, 9:14 PM
Ardent Health Discusses Growth Strategy, Margin Expansion, and Capital Deployment
ARDT
New Projects/Investments
Share Buyback
Guidance Update
- Ardent Health is pursuing a "tri-part growth thesis" focused on expanding its outpatient footprint, which has included adding over 27 urgent cares in the last year and a half, opportunistic M&A, and margin expansion, with confidence in achieving mid-single digit organic growth.
- The company has implemented "impact initiatives" with $40 million of activity already completed, primarily labor-related, which will be fully realized next year, and anticipates margins expanding to mid-teens over time despite industry headwinds like payer denials (almost 2x higher in managed products) and elevated professional fees.
- Ardent's board authorized a $50 million share repurchase, and the company plans to prioritize de novo Ambulatory Surgery Center (ASC) builds, which offer a more attractive growth algorithm (building at 2X multiple versus acquiring at 10X).
- Investments in technology, such as ambient listening, are being rolled out across the platform, with a pilot demonstrating a 4.5-hour reduction in documentation time per physician, aiming to enhance productivity and address workforce challenges.
Nov 18, 2025, 4:00 PM
Ardent Health Announces Share Repurchase and Discusses Growth Strategy, Headwinds
ARDT
Share Buyback
Guidance Update
New Projects/Investments
- Ardent Health announced a $50 million share repurchase authorization, viewing it as a prudent deployment of capital given its strong balance sheet, modest leverage of 2.5 times on a lease-adjusted basis, and over $800 million in available liquidity.
- The company's growth strategy focuses on expanding its outpatient footprint (having added over 27 urgent cares in the last 1.5 years), opportunistic M&A in mid-size urban markets, and margin expansion through "impact initiatives".
- Ardent is addressing industry headwinds including payer denials and elevated professional fees, particularly in radiology and anesthesiology, which have persisted longer and with greater intensity than expected.
- $40 million of impact initiatives have been completed, primarily labor-related through workforce optimization and contract renegotiation, which will contribute to Q4 and a full year impact next year, with further opportunities identified.
- The company remains confident in its long-term organic growth target of mid-single digits, potentially reaching high single digits with capital deployment, driven by population growth in its markets and outpatient expansion.
Nov 18, 2025, 4:00 PM
Ardent Health Announces Share Repurchase Authorization and Discusses Growth Strategy
ARDT
Share Buyback
New Projects/Investments
Guidance Update
- Ardent Health announced a $50 million share repurchase authorization, citing a strong balance sheet with modest leverage and over $800 million in available liquidity.
- The company's growth strategy focuses on expanding its outpatient footprint, having added over 27 urgent cares in the last 18 months, and pursuing opportunistic M&A.
- Ardent has implemented $40 million in impact initiatives that are already in place and will be reflected in next year's run rate, aimed at improving margins.
- The company is actively addressing industry headwinds such as increased payer denials and rising professional fees, particularly in radiology, through renegotiated contracts and a new revenue integrity team.
- Ardent plans to deploy more capital into Ambulatory Surgery Center (ASC) builds in its core growth markets, viewing this as a capital-efficient growth strategy.
Nov 18, 2025, 4:00 PM
Ardent Health Reports Strong Q3 2025 Revenue and EBITDA Growth, Revises Full-Year Guidance Downward
ARDT
Earnings
Guidance Update
Profit Warning
- Ardent Health reported Q3 2025 Adjusted EBITDA of $143 million, a 46% increase year-over-year, with margins expanding 240 basis points to 9.1%. Revenue grew 8.8% to $1.58 billion.
- The company revised its full-year 2025 Adjusted EBITDA guidance to $530 million-$555 million from previous expectations, citing persistent industry-wide cost pressures, including accelerated professional fee growth (11% in Q3) and worsening payer denials.
- To mitigate these challenges, Ardent Health is implementing an "Impact program" with initiatives like contract renegotiations and staffing adjustments, which are expected to generate an annual benefit of more than $40 million by early 2026.
- Operational metrics for Q3 2025 demonstrated strong demand, with admissions growth of 5.8% and adjusted admissions up 2.9%.
- The company maintained a strong financial position, ending Q3 2025 with $609 million in cash and total available liquidity of $904 million, while improving its lease-adjusted net leverage to 2.5x.
Nov 13, 2025, 2:00 PM
Ardent (ARDT) Reports Q3 2025 Results and Revises Full-Year Adjusted EBITDA Guidance
ARDT
Earnings
Guidance Update
Accounting Changes
- Ardent (ARDT) reported Q3 2025 revenue of $1.58 billion, an 8.8% increase (or 11.7% excluding a one-time adjustment), and adjusted EBITDA of $143 million, up 46%. However, the company revised its full-year 2025 adjusted EBITDA guidance to $530 million-$555 million (implying 9% growth at the midpoint), while maintaining revenue guidance.
- The revision in adjusted EBITDA guidance is attributed to persistent industry-wide cost pressures, particularly professional fees, which accelerated to an 11% increase in Q3 2025, and worsening payer denial dynamics.
- To address these challenges, Ardent has launched an "Impact program" with initiatives including contract renegotiations and targeted staffing adjustments, expected to generate an annual benefit of more than $40 million by early 2026.
- Non-recurring items in Q3 2025 included a $43 million revenue reduction due to an accounting estimate change and a $54 million increase in professional and general liability reserves, both of which were excluded from adjusted EBITDA and did not factor into the revised guidance.
Nov 13, 2025, 2:00 PM
Quarterly earnings call transcripts for Ardent Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more